Public Release: 

Giving chemotherapy after radiotherapy improves survival for patients with rare brain tumour

Cancer Research UK

GIVING chemotherapy after radiotherapy delays further growth of a rare type of brain tumour, increasing the number of patients alive at five years from 44 per cent to 56 per cent.

These results - from a clinical trial for patients with anaplastic glioma run by the European Organisation for Research and Treatment of Cancer (EORTC) and funded in UK by Cancer Research UK - were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago today (Friday)*.

The phase III clinical trial compared survival for patients whose tumours were thought to be less likely to respond to chemotherapy because they did not have mutations in two genes called 1p and 19q.

750 patients from institutes around the world were split into four groups and either given:

    1. Radiotherapy alone

    2. Radiotherapy at the same time as chemotherapy

    3. Radiotherapy then chemotherapy

    4. Radiotherapy at the same time as and followed by chemotherapy.

Giving chemotherapy after radiotherapy (groups three and four) halted tumour growth for 43 months after treatment, compared with 19 months for those who only had radiotherapy (groups one and two).

This improvement resulted in 56 per cent of patients given radiotherapy then chemotherapy surviving for five years, compared with only 44 per cent of those who did not.

While giving chemotherapy after radiotherapy has improved survival and is now standard care for these patients, the benefits of chemotherapy at the same time as radiotherapy are still unclear and need further follow-up.

Around 280 people are diagnosed with anaplastic gliomas each year in England.

UK trial lead Dr Sara Erridge, consultant oncologist at the Edinburgh Cancer Centre, said: "Our important study showed that giving temozolomide chemotherapy after radiotherapy delays progression and significantly improves survival for this group of patients. This trial has changed the way we manage patients with this type of tumour with radiotherapy followed by temozolomide chemotherapy now being the standard of care."

Martin van den Bent, member of the EORTC Board and study coordinator, said: "This study demonstrates the value of collaborative academic research in improving the standard of care for rare cancers. Through this partnership between EORTC, Cancer Research UK, North American and Australian study groups we were able to involve a large enough group of patients with this rare tumor type, allowing us to draw definitive conclusions that guide future treatment decisions in this disease."

Cancer Research UK scientists led the development of temozolomide chemotherapy, including its discovery in the lab and the development and first clinical trials of the drug in cancer patients**. The treatment is used worldwide to treat glioblastoma - the most common type of adult primary brain tumour.

Dr Ian Walker, Cancer Research UK's director of clinical research, said: "The data from this trial is an important step forward for patients with anaplastic glioma. Many types of brain cancer are difficult to treat which is why we have committed to investing in more research in these hard-to-treat cancers. It wouldn't have been possible for our researchers to discover and develop temozolomide without the generous donations of our supporters. And thanks to research like this we hope to be able to increase survival for more patients in the future."


For media enquiries contact Emily Head in the Cancer Research UK press office on 020 3469 6189 or, out of hours, on 07050 264 059.

Notes to editor:

* More information about the BR14/CATNON trial available here:

** More information available here:


The European Organisation for the Research and Treatment of Cancer (EORTC) brings together European cancer clinical research experts from all disciplines for trans-national collaboration. Both multinational and multidisciplinary, the EORTC Network comprises more than 4,500 collaborators from all disciplines involved in cancer treatment and research in more than 600 hospitals in over 30 countries. Through translational and clinical research, the EORTC offers an integrated approach to drug development, drug evaluation programs and medical practices.

About the MRC

The Medical Research Council is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers' money in some of the best medical research in the world across every area of health. Thirty-one MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms.

About Cancer Research UK

  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.

  • Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.

  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.

  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.

  • Today, 2 in 4 people will survive their disease for 10 years or more after a cancer diagnosis. Cancer Research UK's ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their disease for 10 years or more after a cancer diagnosis.

  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.

  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit Follow us on Twitter and Facebook.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.